Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Gastroparesis Drugs Market

Gastroparesis Drugs Market Trends

Report ID: GMI9322
Published Date: May 2024
Report Format: PDF

Download Free Sample

Gastroparesis Drugs Market Trends

The demand for the treatment of gastroparesis fuels research and development activities in the pharmaceutical industry, leading to the introduction of new drugs tailored to address the symptoms and underlying causes of gastroparesis. For instance, as per an article published in National Institute of Health in August 2022, it has been reported that prevalence of gastroparesis is 267.7 per 100,000 adults in the U.S. However, a population?based estimate suggests that up to 1.8% of the population is affected. Therefore, as awareness about gastroparesis improves among healthcare professionals and patients, there is greater diagnosis and treatment-seeking behavior, further propelling the demand for gastroparesis drugs.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Gastroparesis drugs industry size was USD 5.9 billion in 2023 and will depict a 5% CAGR from 2024 to 2032 due to the increasing prevalence of gastroparesis globally, particularly among diabetic patients, rising awareness about the condition, and advancements in diagnostic techniques.

The diabetes gastroparesis segment captured 44.6% of the market share in 2023, driven by the escalating prevalence of diabetes worldwide coupled with the consequential rise in gastroparesis cases among diabetic patients.

North America gastroparesis drugs industry will record USD 3.5 billion by 2032, attributed to advanced healthcare infrastructure, high awareness about gastroparesis, and robust R&D activities.

Key gastroparesis drug firms are Abbott Laboratories, AbbVie Inc., AstraZeneca PLC, Bayer AG, Cipla Ltd., Evoke Pharma, Pfizer Inc., Salix Pharmaceuticals, Takeda Pharmaceutical, Inc., and Teva Pharmaceutical Inc., among others.